beREADY test is available in our partner clinics

Please e-mail us beready@ccht.ee and ask more information providing your name, position (patient or physician), location and how we can help you?

Mehiläinen  (Helsinki, Turku, Oulu)
Dextra clinic (Helsinki)
InOva clinic (Kuopio)
Genesis (Saint Petersburg)
D.O.Ott  (Saint Petersburg)
SM-Clinic (Moscow)
EGV (Riga)
New Life India (New Delhi)



Endometrial sampling by Pipelle catheter is taken one or more cycles before embryo transferring. The biopsy timing and hormone replacement therapy (HRT) chema should be identical in following the embryo transferring plan in the following cycle. It is like a preparative simulation for gaining confidence before embryo(s) are involved.

The patient should be informed by a clinician about the benefits and outcome of the test. Patient-informed consent should be signed before sampling.


An endometrial tissue sample is preserved in a special solution and shipped at room temperature to the beREADY laboratory.


The analysis begins once the tissue sample has arrived together with the completed order form and signed patient consent form. The analysis is based on gene expression biomarker profiling, which reflects the readiness of the receptive endometrium. RNA material is extracted from the biopsy and 67 informative biomarker genes are analysed. The most up-to-date TAC-seq protocol combined with Illumina sequencing technology is applied.


The beREADY test results are sent to the physician by email within 14 business days of receiving the biopsy and completed documents at the laboratory.


The beREADY test measures the readiness of the endometrium for successful embryo implantation. The test results are reported in three main categories.
The endometrium may be:

1. RECEPTIVE (optimal day for embryo transfer)

2. PRE-RECEPTIVE (the tissue needs extra time to mature)

3. POST-RECEPTIVE (receptive period is over)

Based on the possible results, practical recommendations are provided for the clinician.

More specifically, the detected receptivity is expressed as a score on the Receptometer chart. Selected possible scenarios:

The biopsy is PRE-receptive. The arrow is not in the green sector. It is not perfect time for D5 embryo transferring. The beREADY recommendation is to perform a re-biopsy after 24 h. A re-biopsy is required to be confident that receptivity is achieved before embryo transferring.

The biopsy is receptive BUT maximum is achieved in probably 12-24 h. The sample is defined as early-receptive.
beREADY does not recommend re-biopsy.

The biopsy is receptive. It is the perfect time for D5 embryo transferring in the next cycle.

The biopsy is still receptive BUT tissue maturation has been quicker and there is a risk of transferring the embryo too late. According to the beREADY recommendation, the embryo should be transferred 12-24 h in advance. The sample is defined as late-receptive.

The red timeline shows the dynamic from PRE-receptive time to the POST-receptive phase. It may last a number of days. In the beREADY report, only one detected status is reported. The Receptometer chart provides information for a possible follow-up biopsy to see the effect of ART adjustment.